Illumina Stock Price, News & Analysis (NASDAQ:ILMN)

$309.57
+4.37 (+1.43 %)
(As of 09/20/2019 04:00 PM ET)
Today's Range
$303.00
Now: $309.57
$310.39
50-Day Range
$267.39
MA: $287.68
$306.34
52-Week Range
$263.30
Now: $309.57
$380.76
Volume1.07 million shs
Average Volume1.08 million shs
Market Capitalization$45.51 billion
P/E Ratio52.33
Dividend YieldN/A
Beta1.09
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.33 billion
Cash Flow$7.4362 per share
Book Value$26.16 per share

Profitability

Net Income$826 million

Miscellaneous

Employees7,300
Market Cap$45.51 billion
Next Earnings Date10/22/2019 (Estimated)
OptionableOptionable

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.


Illumina (NASDAQ:ILMN) Frequently Asked Questions

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) issued its earnings results on Monday, July, 29th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.32 by $0.03. The life sciences company had revenue of $838 million for the quarter, compared to analysts' expectations of $835.12 million. Illumina had a return on equity of 21.73% and a net margin of 27.56%. Illumina's quarterly revenue was up 1.0% compared to the same quarter last year. During the same period last year, the business earned $1.43 EPS. View Illumina's Earnings History.

When is Illumina's next earnings date?

Illumina is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for Illumina.

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its FY19 earnings guidance on Monday, July, 29th. The company provided EPS guidance of $6.00 to $6.10 for the period, compared to the Thomson Reuters consensus estimate of $6.38. The company issued revenue guidance of ~6% (~$3.53 billion), compared to the consensus revenue estimate of $3.62 billion.

What price target have analysts set for ILMN?

13 analysts have issued 1 year price targets for Illumina's shares. Their forecasts range from $280.00 to $370.00. On average, they expect Illumina's stock price to reach $328.7273 in the next year. This suggests a possible upside of 6.2% from the stock's current price. View Analyst Price Targets for Illumina.

What is the consensus analysts' recommendation for Illumina?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Illumina.

What are Wall Street analysts saying about Illumina stock?

Here are some recent quotes from research analysts about Illumina stock:
  • 1. Canaccord Genuity analysts commented, "We don’t believe an ultra-premium multiple is now justified for a company looking to grow +6% on the top and bottom lines, which now seem more vulnerable to large misses. What’s more, we lack visibility to 2020 or 2021 growth rates given a wide range of moving parts. We would look to get more constructive if our concerns prove to be transitory, or if ILMN announces the $100 genome at a price point that would meaningfully accelerate its top line and not add further headwinds to its gross, operating or net income margins. ILMN is working hard to drive down the cost of sequencing to be able to usher in the eagerly awaited $100 genome. DTC troubles. On the call, Illumina CEO Francis deSouza indicated he expects a DTC reacceleration “in the coming years,” which to us doesn’t imply a recovery in 2020." (7/30/2019)
  • 2. According to Zacks Investment Research, "Illumina continues to register strong top line growth across the company’s high throughput, mid throughput and low throughput categories. In the last-reported fourth quarter, the company observed strong demand for sequencing and array systems, consumables and services. Meanwhile HiSeq to NovaSeq upgrade cycle is progressing well and NextSeq placements are strong. We are also looking forward to the company's newly-inked Pacific Biosciences deal. In the past year, Illumina has outperformed its industry. However, we note that, Illumina exited the fourth quarter of 2018 on a mixed note with earnings lagging the Zacks Consensus Estimate. HiSeq consumables are continuing with their expected decline. Seasonality in DTC functionality continues to dent Illumina’s microarray sales. Funding issues restrict growth. The company is operating in a tough competitive landscape." (4/2/2019)

Has Illumina been receiving favorable news coverage?

News coverage about ILMN stock has been trending negative on Saturday, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Illumina earned a coverage optimism score of -2.9 on InfoTrie's scale. They also assigned press coverage about the life sciences company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Illumina.

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Adobe (ADBE), Baidu (BIDU), Gilead Sciences (GILD), Visa (V), Celgene (CELG), Tesla (TSLA) and Micron Technology (MU).

Who are Illumina's key executives?

Illumina's management team includes the folowing people:
  • Mr. Jay T. Flatley, Exec. Chairman (Age 66)
  • Mr. Francis A. deSouza, CEO, Pres & Director (Age 48)
  • Mr. Sam A. Samad, CFO & Sr. VP (Age 49)
  • Mr. Omead Ostadan, Sr. VP of Products, Marketing & Strategic Planning (Age 47)
  • Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 48)

Who are Illumina's major shareholders?

Illumina's stock is owned by a number of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.41%), Vanguard Group Inc. (7.76%), Jennison Associates LLC (4.07%), Edgewood Management LLC (2.83%), Nuveen Asset Management LLC (1.54%) and Northern Trust Corp (1.14%). Company insiders that own Illumina stock include A Blaine Bowman, Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Robert P Ragusa and Robert S Epstein. View Institutional Ownership Trends for Illumina.

Which institutional investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including CQS Cayman LP, Man Group plc, Nomura Holdings Inc., Nomura Holdings Inc., Bank of New York Mellon Corp, Price T Rowe Associates Inc. MD, Janus Henderson Group PLC and Janus Henderson Group PLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Robert P Ragusa and Robert S Epstein. View Insider Buying and Selling for Illumina.

Which institutional investors are buying Illumina stock?

ILMN stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Thoroughbred Financial Services LLC, Baillie Gifford & Co., Jennison Associates LLC, Nikko Asset Management Americas Inc., Bessemer Group Inc., Viking Global Investors LP and WCM Investment Management LLC. View Insider Buying and Selling for Illumina.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $309.57.

How big of a company is Illumina?

Illumina has a market capitalization of $45.51 billion and generates $3.33 billion in revenue each year. The life sciences company earns $826 million in net income (profit) each year or $5.72 on an earnings per share basis. Illumina employs 7,300 workers across the globe.View Additional Information About Illumina.

What is Illumina's official website?

The official website for Illumina is http://www.illumina.com/.

How can I contact Illumina?

Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]


MarketBeat Community Rating for Illumina (NASDAQ ILMN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  948 (Vote Outperform)
Underperform Votes:  838 (Vote Underperform)
Total Votes:  1,786
MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe ILMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ILMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2019 by MarketBeat.com Staff

Featured Article: Municipal Bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel